Olympus Corporation
Fiscal Year Ending March 2027 Q2 Consolidated Financial Summary
Revenue was 269.2 billion yen (Year-over-Year +9%), adjusted operating margin 17.8%, adjusted EPS 32 yen. The first half demonstrates progress against the FY2027–FY2029 plan, with continued growth in GIS and urology/respiratory segments. Full-year outlook has been revised upward. Impact from FDA corrective actions and import warnings is viewed as limited. The acquisition of BioProtect and other transactions affected the financials.
Key Figures
- Revenue: 269.2 hundred million yen (Year-over-Year +9%)
- Adjusted EPS: 32 yen (Year-over-Year +38%)
- Adjusted Operating Margin: 17.8% (Year-over-Year +2.8pp)
AI要約
Performance Overview
In Q2, priority initiatives across finance, operations and strategy progressed smoothly. Strong growth in GIS and continued double-digit growth in urology and respiratory segments drove overall revenue increases year-on-year. The first-half targets under the FY2027–FY2029 plan were steadily achieved, leading to an upward revision of the full-year lower bound. FDA-related corrective actions are ongoing, but are not expected to have a material impact on consolidated results for FY2027. Integration of BioProtect and expansion of the new portfolio are also underway.
Outlook and Key Drivers
First-half growth was supported by strong execution of GIS in North America, Europe and APAC, with product lines in urology and respiratory remaining robust. Full-year guidance is revenue 1,064.5 hundred million yen to 1,076.0 hundred million yen, adjusted EPS 111 yen to 119 yen (lower bound TBD), and an annual dividend of 30 yen is planned. While continuing responses to FDA import warnings and quality corrective actions, capital strategy is being advanced with consideration of the BioProtect acquisition impact.
Revenue Trend
Operating Profit Trend
Margin Trend
Segment Revenue Breakdown
Olympus Corporation
Company overview · Stock price · Financial data · All IR
